OncoMatch/Clinical Trials/NCT06748001

Avapritinib Rollover Study

Is NCT06748001 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Avapritinib for mastocytosis, systemic.

Phase 4RecruitingBlueprint Medicines CorporationNCT06748001Data as of May 2026

Treatment: Avapritinib — The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Check if I qualify

Extracted eligibility criteria

Prior therapy

Must have received: avapritinib (avapritinib) — Blueprint Medicines sponsored avapritinib clinical study

Participated in a Blueprint Medicines sponsored avapritinib clinical study

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify